Found: 200
Select item for more details and to access through your institution.
Intestinal Microbiota and Short-Chain Fatty Acids in Association with Advanced Metrics of Glycemia and Adiposity Among Young Adults with Type 1 Diabetes and Overweight or Obesity.
- Published in:
- Current Developments in Nutrition, 2022, v. 6, n. 10, p. 1, doi. 10.1093/cdn/nzac107
- By:
- Publication type:
- Article
Beyond the Cox Hazard Ratio: A Targeted Learning Approach to Survival Analysis in a Cardiovascular Outcome Trial Application.
- Published in:
- Statistics in Biopharmaceutical Research, 2023, v. 15, n. 3, p. 524, doi. 10.1080/19466315.2023.2173644
- By:
- Publication type:
- Article
Measurement of altered APP isoform expression in adipose tissue of diet-induced obese mice by absolute quantitative real-time PCR.
- Published in:
- Animal Cells & Systems, 2017, v. 21, n. 2, p. 100, doi. 10.1080/19768354.2017.1290679
- By:
- Publication type:
- Article
Improved glucose tolerance with restored expression of glucose transporter 4 in C57BL/6 mice after a long period of high-fat diet feeding.
- Published in:
- Animal Cells & Systems, 2014, v. 18, n. 3, p. 197, doi. 10.1080/19768354.2014.924995
- By:
- Publication type:
- Article
Altered gene expression of amyloid precursor protein in the adipose tissue and brain of obese mice fed with long-term high-fat diet and streptozotocin-induced diabetic mice.
- Published in:
- Animal Cells & Systems, 2014, v. 18, n. 4, p. 219, doi. 10.1080/19768354.2014.940383
- By:
- Publication type:
- Article
Dysregulation of cannabinoid CB1 receptor expression in subcutaneous adipocytes of obese individuals.
- Published in:
- Animal Cells & Systems, 2009, v. 13, n. 4, p. 371, doi. 10.1080/19768354.2009.9647232
- By:
- Publication type:
- Article
The independent and combined effects of weight loss and aerobic exercise on blood pressure and oral glucose tolerance in older men<sup>*</sup>.
- Published in:
- American Journal of Hypertension, 1998, v. 11, n. 12, p. 1405, doi. 10.1016/S0895-7061(98)00185-X
- By:
- Publication type:
- Article
Investigation of Extracellular Vesicles From SARS-CoV-2 Infected Specimens: A Safety Perspective.
- Published in:
- Frontiers in Immunology, 2021, v. 11, p. N.PAG, doi. 10.3389/fimmu.2021.617042
- By:
- Publication type:
- Article
24-h energy expenditure in people with type 1 diabetes: impact on equations for clinical estimation of energy expenditure.
- Published in:
- European Journal of Clinical Nutrition, 2024, v. 78, n. 8, p. 718, doi. 10.1038/s41430-024-01446-4
- By:
- Publication type:
- Article
Host-diet-gut microbiome interactions influence human energy balance: a randomized clinical trial.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-38778-x
- By:
- Publication type:
- Article
Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial.
- Published in:
- European Heart Journal, 2023, v. 44, n. 48, p. 5163, doi. 10.1093/eurheartj/ehad639
- By:
- Publication type:
- Article
Ezetimibe/simvastatin or atorvastatin for the treatment of hypercholesterolemia in patients with the metabolic syndrome: the VYMET study.
- Published in:
- 2010
- By:
- Publication type:
- journal article
Weight loss and diets: which diet works best?
- Published in:
- 2009
- By:
- Publication type:
- journal article
LAP-BAND or medical therapy for metabolic syndrome?
- Published in:
- 2008
- By:
- Publication type:
- journal article
Cardiovascular Outcome Trials with Glucose-Lowering Drugs.
- Published in:
- Current Cardiology Reports, 2021, v. 23, n. 7, p. 1, doi. 10.1007/s11886-021-01505-3
- By:
- Publication type:
- Article
Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms.
- Published in:
- Endocrine Reviews, 2018, v. 39, n. 5, p. 629, doi. 10.1210/er.2017-00191
- By:
- Publication type:
- Article
Effects of ertugliflozin on uric acid and gout‐related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CV.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 11, p. 5336, doi. 10.1111/dom.15895
- By:
- Publication type:
- Article
Hypoglycaemia and kidney events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 8, p. 3478, doi. 10.1111/dom.15687
- By:
- Publication type:
- Article
Effect of albiglutide on cardiovascular outcomes in older adults: A post hoc analysis of a randomized controlled trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 5, p. 1714, doi. 10.1111/dom.15479
- By:
- Publication type:
- Article
Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 5, p. 1398, doi. 10.1111/dom.14965
- By:
- Publication type:
- Article
Body weight loss with oral semaglutide is mediated predominantly by effects other than gastrointestinal adverse events in patients with type 2 diabetes: A post hoc analysis.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 4, p. 1130, doi. 10.1111/dom.14957
- By:
- Publication type:
- Article
Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium‐glucose cotransporter‐2 inhibitor ertugliflozin
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 758, doi. 10.1111/dom.14923
- By:
- Publication type:
- Article
Weight management in young adults with type 1 diabetes: The advancing care for type 1 diabetes and obesity network sequential multiple assignment randomized trial pilot results.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 688, doi. 10.1111/dom.14911
- By:
- Publication type:
- Article
Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 9, p. 1829, doi. 10.1111/dom.14769
- By:
- Publication type:
- Article
Linagliptin use in older individuals with type 2 diabetes.
- Published in:
- Clinical Interventions in Aging, 2014, v. 9, p. 1109, doi. 10.2147/CIA.S62877
- By:
- Publication type:
- Article
An Overview of Diet and Physical Activity for Healthy Weight in Adolescents and Young Adults with Type 1 Diabetes: Lessons Learned from the ACT1ON Consortium.
- Published in:
- Nutrients, 2023, v. 15, n. 11, p. 2500, doi. 10.3390/nu15112500
- By:
- Publication type:
- Article
"Tasting" fructose with pancreatic beta-cells: modulation of insulin release by sweet taste receptor signaling and its role in metabolic diseases.
- Published in:
- 2012
- By:
- Publication type:
- Abstract
Relationship of the white blood cell count to body fat: role of leptin.
- Published in:
- British Journal of Haematology, 1997, v. 99, n. 2, p. 447, doi. 10.1046/j.1365-2141.1997.3873201.x
- By:
- Publication type:
- Article
Obesity and asthma: an inflammatory disease of adipose tissue not the airway.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Obesity and Asthma.
- Published in:
- American Journal of Respiratory & Critical Care Medicine, 2012, v. 186, n. 7, p. 598, doi. 10.1164/rccm.201203-0573OC
- By:
- Publication type:
- Article
Effects of glucose and insulin on secretion of amyloid-β by human adipose tissue cells.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Adipose tissue natriuretic peptide receptor expression is related to insulin sensitivity in obesity and diabetes.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose‐lowering agent: An analysis from VERTIS CV.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 7, p. 1245, doi. 10.1111/dom.14691
- By:
- Publication type:
- Article
The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 6, p. 1114, doi. 10.1111/dom.14677
- By:
- Publication type:
- Article
Indirect treatment comparisons: Choosing the right tool for the job.
- Published in:
- 2022
- By:
- Publication type:
- Letter to the Editor
An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 11, p. 2513, doi. 10.1111/dom.14497
- By:
- Publication type:
- Article
Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 9, p. 2058, doi. 10.1111/dom.14443
- By:
- Publication type:
- Article
Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase‐4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 2, p. 569, doi. 10.1111/dom.14254
- By:
- Publication type:
- Article
Development of a hypoglycaemia risk score to identify high‐risk individuals with advanced type 2 diabetes in DEVOTE.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 12, p. 2248, doi. 10.1111/dom.14208
- By:
- Publication type:
- Article
Effects of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 12, p. 2487, doi. 10.1111/dom.14160
- By:
- Publication type:
- Article
Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 12, p. 2241, doi. 10.1111/dom.14049
- By:
- Publication type:
- Article
Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 11, p. 2193, doi. 10.1111/dom.14140
- By:
- Publication type:
- Article
Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 11, p. 2077, doi. 10.1111/dom.14126
- By:
- Publication type:
- Article
The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 9, p. 1690, doi. 10.1111/dom.14079
- By:
- Publication type:
- Article
Validation of distinct type 2 diabetes clusters and their association with diabetes complications in the DEVOTE, LEADER and SUSTAIN‐6 cardiovascular outcomes trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 9, p. 1537, doi. 10.1111/dom.14063
- By:
- Publication type:
- Article
Evaluating glucose‐lowering treatment in older people with diabetes: Lessons from the IMPERIUM trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 8, p. 1231, doi. 10.1111/dom.14013
- By:
- Publication type:
- Article
Long‐term efficacy and safety of combined insulin and glucagon‐like peptide‐1 therapy: Evidence from the LEADER trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 11, p. 2450, doi. 10.1111/dom.13826
- By:
- Publication type:
- Article
Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 11, p. 2429, doi. 10.1111/dom.13824
- By:
- Publication type:
- Article
Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 7, p. 1745, doi. 10.1111/dom.13698
- By:
- Publication type:
- Article
Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7).
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 7, p. 1625, doi. 10.1111/dom.13699
- By:
- Publication type:
- Article